Novartis has secured FDA approval for its BTK inhibitor remibrutinib (Rhapsido) for the treatment of chronic spontaneous urticaria. Remibrutinib is the sixth BTK inhibitor to market in the US, and the ...

Sexuality and disability can interact with one another in complex ways. For some, disability has no effect on sexual desire or activity, while for others, it may pose challenges. Sometimes, these ...

Italy and Spain have sent naval vessels to assist the Global Sumud Flotilla as it sails to take aid to Gaza. The “unprecedented move” from the two governments follows “repeated attacks” against the ...

Rhapsido is the first FDA-approved BTKi for CSU, targeting patients unresponsive to H1 antihistamines. REMIX trials showed Rhapsido's superiority over placebo in reducing CSU symptoms by Week 12.

Does everybody know what time it is? It’s time to check up on the cast of the 1991 sitcom “Home Improvement.” The ABC show aired from September 1991 to May 1999 and featured Tim Allen as Tim “The Tool ...

The Race and Medicine collection reflects NEJM’s commitment to understanding and combating racism as a public health and human rights crisis. Our commitment to antiracism includes efforts to educate ...

The Poverty and Equity Briefs (PEBs) highlight poverty, shared prosperity and inequality trends for over 100 developing countries. The briefs are released twice a year for the Spring and Annual ...

As a writer for Forbes Home since 2021, Emily specializes in writing about home warranties, solar installations, car transportation and moving companies. With a background in journalism and experience ...

“CSU is a serious disease that can cause debilitating symptoms and unpredictable flares. It’s difficult to diagnose and manage,” said Mark Lebwohl, MD, Dean for Clinical Therapeutics at the Icahn ...

OpenAI is an artificial intelligence organization comprised of the non-profit OpenAI, Inc. and several for-profit subsidiaries. The company is perhaps best known for its ChatGPT chatbot, which ...

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday. Indicated for adults with stubborn ...